SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 214 filers reported holding SAGE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,042,665 | +6.5% | 50,664 | +143.3% | 0.01% | -16.7% |
Q2 2023 | $979,097 | +74412.7% | 20,823 | -33.5% | 0.01% | -40.0% |
Q1 2023 | $1,314 | -99.8% | 31,323 | +82.0% | 0.02% | +33.3% |
Q3 2022 | $674,000 | -43.8% | 17,207 | -53.7% | 0.02% | -51.6% |
Q2 2022 | $1,200,000 | +178.4% | 37,165 | +646.6% | 0.03% | +158.3% |
Q4 2020 | $431,000 | +98.6% | 4,978 | -4.4% | 0.01% | +9.1% |
Q2 2020 | $217,000 | -63.2% | 5,207 | -36.2% | 0.01% | -57.7% |
Q4 2019 | $590,000 | -29.4% | 8,166 | +52.9% | 0.03% | -10.3% |
Q2 2018 | $836,000 | +260.3% | 5,341 | +279.3% | 0.03% | +383.3% |
Q4 2017 | $232,000 | -22.7% | 1,408 | -70.8% | 0.01% | -25.0% |
Q3 2017 | $300,000 | +27.7% | 4,815 | +62.9% | 0.01% | +14.3% |
Q2 2017 | $235,000 | -66.9% | 2,955 | -80.9% | 0.01% | -58.8% |
Q3 2016 | $711,000 | +152.1% | 15,449 | +64.8% | 0.02% | +183.3% |
Q2 2016 | $282,000 | +23.1% | 9,373 | +199.4% | 0.01% | -14.3% |
Q2 2015 | $229,000 | – | 3,131 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sio Capital Management, LLC | 179,200 | $29,516,000 | 16.65% |
TRV GP II, LLC | 547,916 | $90,247,000 | 16.25% |
Opus Point Partners Management, LLC | 71,000 | $11,694,000 | 10.12% |
Casdin Capital, LLC | 250,000 | $41,178,000 | 10.03% |
RA Capital Management | 455,173 | $74,972,000 | 6.27% |
Crawford Lake Capital Management, LLC | 154,278 | $25,411,000 | 6.00% |
Palo Alto Investors LP | 810,806 | $133,548,000 | 5.75% |
GREAT POINT PARTNERS LLC | 200,000 | $32,942,000 | 5.62% |
BB BIOTECH AG | 1,042,439 | $171,700,000 | 4.84% |
Crawford Lake Capital Management, LLC | 92,300 | $15,203,000 | 3.59% |